

Atty. Dkt. No. 034536-0839

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Benjamin L. MARGOLIS
Title: METHODS AND COMPOSITIONS FOR TREATMENT OF BREAST CANCER
Appl. No.: 10/679,694
Filing Date: 10/07/2003
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

Applicant submits herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/458,631, filed 12/10/1999, which is a division of application Serial No. 08/472,595, filed 06/06/1995, which is a division of application Serial No. 08/207,575, filed 03/07/1994. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent applications.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE


The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date February 12, 2004

By 

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/679,694
Sheet		1	of	6	Filing Date 10/07/2003 First Named Inventor Benjamin L. Margolis Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number 034536-0839

FEB 12 2004

PATENT & TRADEMARK

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,196,446		LEVITZKI et al.	03-23-1993	
	A2	5,217,999		LEVITZKI et al.	06-08-1993	
	A3	5,352,660		PAWSON	10-04-1994	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	BARGMAN et al., "The neu Oncogene Encodes for an Epidermal Growth Factor Receptor-Related Protein," <u>Nature</u> , 1986, pp. 226-230, Vol. 319	
	A5	BELLACOSA et al., "A Retroviral Oncogene, akt Encoding a Serine-Threonine Kinase Containing an SH2-Like Region," <u>Science</u> , 1991, pp. 274-277, Vol. 254	
	A6	BOWCOCK et al., "THRA1 and D17S183 Frank an Integral of <4 cM for the Breast-Ovarian Cancer Gene (BRCA1) on Chromosome 17q21," <u>Am. J. Hum. Genetics</u> , 1993, pp. 718-722, Vol. 52	
	A7	BUCHBERG et al., "A Comprehensive Genetic Map of Murine Chromosome 11 Reveals Extensive Linkage Conservation Between Mouse and Human," <u>Genetics</u> , 1989, pp. 153-161, Vol. 122	
	A8	BUDAY et al., <u>Mol. Cell. Biol.</u> , 1993, pp. 1903-1910, Vol. 13	
	A9	CANTLEY et al., "Oncogenes and Signal Transduction," <u>Cell</u> , 1991, pp. 281-302. Vol. 64	
	A10	CIOCCA et al., "Correlation of HER-2/neu Amplification with Expression and with Other Prognostic Factors in 1103 Breast Cancers," <u>JNCI</u> , 1992, pp. 1279-1282, Vol. 84	
	A11	COUSSENS et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with new Oncogene," <u>Science</u> , 1985, pp. 1132-1139, Vol. 230	
	A12	<u>Current Protocols in Molecular Biology</u> , John Wiley & Sons, 1987, pp. 10.11.1-0.11.7	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/679,694
		Filing Date	10/07/2003
		First Named Inventor	Benjamin L. Margolis
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-0839
Sheet	2	of	6



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A13	DOWNWARD et al., "Close Similarity of Epidermal Growth Factor Receptor and v-erb-B Oncogene Protein Sequences," <u>Nature</u> , 1984, pp. 521-527, Vol. 307	
	A14	EGAN et al., "Association of Sos Ras Exchange Protein with Grb2 is Implicated in Tyrosine Kinase Signal Transduction and Transformation," <u>Nature</u> , 1993, pp. 450-451, Vol. 363	
	A15	FISCHER et al., "Protein Tyrosine Phosphatases: A Diverse Family of Intracellular and Transmembrane Enzymes," <u>Science</u> , 1991, pp. 401-406, Vol. 253	
	A16	GAZIT et al., "Tyrosinases I: Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <u>J. Medicinal Chem.</u> , 1989, pp. 2344-2354, Vol. 32	
	A17	HANKS et al., "The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains," <u>Science</u> , 1988, pp. 42-52, Vol. 241	
	A18	HARDIE, "Roles of Protein Kinases and Phosphates in Signal Transduction," <u>Symp. Soc. Exp. Biol.</u> , 1990, pp. 241-255, Vol. 44	
	A19	HARLOW et al., <u>Antibodies. A Laboratory Manual</u> , Cold Spring Harbor Laboratory, 1988 (TABLE OF CONTENTS ONLY)	
	A20	HASLAM et al., "Pleckstrin Domain Homology," <u>Nature</u> , 1993, pp. 309-310, Vol. 363	
	A21	HUNTER, "Cooperation Between Oncogenes," <u>Cell</u> , 1991, pp. 249-270, Vol. 64	
	A22	JONES et al., "Molecular Cloning and Identification of a Serine-Threonine Protein Kinases of the Second-Messenger Subfamily," <u>PNAS</u> , 1991, pp. 4171-4175, Vol. 88	
	A23	KING et al., "EGF Binding to its Receptor Triggers a Rapid Tyrosine Phosphorylation of the erbB-2 Protein in the Mammary Tumor Cell Line SK-BR-3," <u>EMBO J.</u> , 1988, pp. 1647-1651, Vol. 7	
	A24	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> , 1992, pp. 668-674, Vol. 252	
	A25	KURY et al., "Determination of HER-2/neu Amplification and Expression in Tumor Tissue and Cultured Cells Using a Simple, Phenol Free Method for Nucleic Acid Isolation," <u>Oncogene</u> , 1990, pp. 1403-1408, Vol. 5	
	A26	LEE et al., "HER2 Cytoplasmic Domain Generates Normal Mitogenic and Transforming Signals in a Chimeric Receptor," <u>EMBO J.</u> , 1989, pp. 167-173, Vol. 8	
	A27	LI et al., "Guanine-Nucleotide-Releasing Factor hSos1 Binds to Grb2 and Links Receptor Tyrosine Kinases to Ras Signalling," <u>Nature</u> , 1993, pp. 85-88, Vol. 363	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/679,694 10/07/2003 Benjamin L. Margolis Unassigned Unassigned 034536-0839
Sheet	3	of	6



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A28	LIPPMAN et al., "The Development of Biological Therapies for Breast Cancer," <u>Science</u> , 1993, pp. 631-632, Vol. 259	
	A29	LYALL et al., "Tyrophostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-Stimulated Cell Proliferation," <u>J. Biol. Chem.</u> , 1989, pp. 14503-14509, Vol. 264	
	A30	MARGOLIS et al., "Effect of Phospholipase C-γ Overexpression of PDGF-Induced Second Messengers and Mitogenesis," <u>Science</u> , 1990, pp. 607-610, Vol. 248	
	A31	MARGOLIS et al., "EGF Induces Tyrosine Phosphorylation of Phospholipase C-II: A Potential Mechanism for EGF Receptor Signalling," <u>Cell</u> , 1989, pp. 1101-1107, Vol. 57	
	A32	MARGOLIS et al., "High-Efficiency Expression/Cloning of Epidermal Growth Factor-Receptor-Binding Proteins with Src Homology," <u>PNAS (USA)</u> , 1992, pp. 8894-8898, Vol. 89	
	A33	MARGOLIS, "Proteins with SH2 Domains: Transducers in the Tyrosine Kinase Signalling Pathway," <u>Cell. Growth. Differ.</u> , 1992, pp. 73-80, Vol. 3	
	A34	MARGOLIS et al., <u>Jnl. Cell Biochem.</u> , Abstract Supplement 18B, Feb. 1994, p. 241, Abstract #1243	
	A35	MARINI et al., "The Pituitary Hormones Arginine Vasopressin-Neurophysin II and Oxytocin-Neurophysin I Show Close Linkage with Interleukin-1 on Mouse Chromosome 2," <u>Genomics</u> , 1993, pp. 200-202, Vol. 15	
	A36	MAYER et al., "A Novel Viral Oncogene with Structural Similarity to Phospholipase C," <u>Nature</u> , 1988, pp. 272-275, Vol. 332	
	A37	MAYER et al., "A Putative Modular Domain Present In Diverse Signalling Proteins," <u>Cell</u> , 1993, pp. 629-630, Vol. 73	
	A38	MAYER et al., <u>Trends in Cell. Biol.</u> , 1993, pp. 8-13, Vol. 3	
	A39	MUSACCHIO et al., "The PH Domain: A Common Piece in the Structural Patchwork of Signalling Proteins," <u>Trends in Biochem. Sci.</u> , 1993, pp. 343-348, Vol. 18	
	A40	NURSE, "Universal Control Mechanism Regulating Onset of M-phase," <u>Nature</u> , 1990, pp. 503-508, Vol. 344	
	A41	OSHEROV et al., "Selective Inhibition of the Epidermal Growth Factor and HER2/Neu Receptors by Tryphostins," <u>J. Biol. Chem.</u> , 1993, pp. 11134-11142, Vol. 268	
	A42	PADHY et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas," <u>Cell</u> , 1982, pp. 865-871, Vol. 28	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/679,694 10/07/2003 Benjamin L. Margolis Unassigned Unassigned 034536-0839
Sheet	4	of	6



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A43	PAWSON et al., "SH2 and SH3 Domains," <u>Current Biol.</u> , 1993, pp. 434-442, Vol. 3, No. 7	
	A44	PAWSON et al., "SH2 and SH3 Domains: From Structure to Function," <u>Cell</u> , 1992, pp. 359-362, Vol. 71	
	A45	PELES et al., "Cell Type Specific Interaction of Neu Differentiation Factor (HDF/hereregulin) with Neu/HER-2 Suggest Complex Ligand-Receptor Relationships," <u>EMBO J.</u> , 1993, pp. 961-971, Vol. 12	
	A46	PENDERGAST et al., "BCR Sequences Essential for Transformation by the BCR-ABL Oncogene Bind to the ABL SH2 Regulatory Domain in a Non-Phosphotyrosine-Dependent Manner," <u>Cell</u> , 1991, pp. 161-171, Vol. 66	
	A47	PLOWMAN et al., "Heregulin Induces Tyrosine Phosphorylation of HER4/p180.sup.erbB4," <u>Nature</u> , 1993, pp. 473-475, Vol. 366	
	A48	PLOWMAN et al., "Ligand-Specific Activation of HER4/p180.sup.erbB4, a Fourth Member of the Epidermal Growth Factor Receptor Family," <u>PNAS</u> , 1993, pp. 1746-1750, Vol. 90	
	A49	POSADA et al., "Molecular Signal Integration. Interplay Between Serine, Threonine, and Tyrosine Phosphorylation," <u>Mol. Biol. Cell</u> , 1992, pp. 583-592, Vol. 3	
	A50	REN et al., "Identification of a Ten-Amino Acid Proline-Rich SH3 Binding Site," <u>Science</u> , 1993, pp. 1157-1161, Vol. 259	
	A51	RON et al., "pGSTag-A Versatile Bacterial Expression Plasmid for Enzymatic Labelling of Recombinant Proteins," <u>Biotechniques</u> , 1992, pp. 866-869, Vol. 13	
	A52	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-Containing Proteins Is Implicated in Activation of the Ras Pathway by Tyrosine Kinases," <u>Nature</u> , 1992, pp. 689-692, Vol. 360	
	A53	SADOWSKI et al., "A Nucleocapsid Domain Conserved Among Cytoplasmic Protein-Tyrosine Kinases Modifies the Kinase Function and Transforming Activity of Fujinami Sarcoma Virus P130.sup.gag-fpe," <u>Mol. Cell. Biol.</u> , 1986, pp. 4396-4408, Vol. 6	
	A54	SAP et al., "Cloning and Expression of a Widely Expressed Receptor Tyrosine Phosphatase," <u>PNAS</u> , 1990, pp. 6112-6116, Vol. 87	
	A55	SCHECHTER et al., "The neu Oncogene: an erb-B-related Gene Encoding is 185,000-M Tumor Antigen," <u>Nature</u> , 1984, pp. 513-516, Vol. 312	
	A56	SCHLESSINGER AND ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> , 1992, pp. 383-397, Vol. 9	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/679,694 10/07/2003 Benjamin L. Margolis Unassigned Unassigned 034536-0839
Sheet	5	of	6



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A57	SCOTT et al., "Serinine/Threonine Protein Kinases," <u>Current Opinion in Neurology</u> , 1992, pp. 289-95, Vol. 2	
	A58	SHEPARD et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," <u>J. Clin. Immunol.</u> , 1991, pp. 117-127, Vol. 11	
	A59	SKOLNICK et al., "The SH2/SH3 Domain-Containing Protein GRB2 Interacts with Tyrosine-Phosphorylated IRS1 and SHc: Implications for Insulin Control of ras Signalling," <u>EMBO J.</u> , 1993, pp. 1929-1936, Vol. 12	
	A60	SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," <u>Science</u> , 1987, pp. 177-182, Vol. 235	
	A61	SLAMON et al., "Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer," <u>Science</u> , 1989, pp. 707-712, Vol. 244	
	A62	SMITH et al., "Topoisomerase II.alpha. co-amplification with erbB2 in Human Primary Breast Cancer and Breast Cancer Cell Lines: Relationship to m-AMSA and mitoxantrone Sensitivity," <u>Oncogene</u> , 1993, pp. 933-938, Vol. 8	
	A63	STAHL et al., "Sequence Similarity of Phospholipase C with the non-catalytic region of src," <u>Nature</u> , 1988, pp. 269-272, Vol. 332	
	A64	SULSTON et al., "The C. elegans Genome Sequencing Project: A Beginning," <u>Nature</u> , 1992, pp. 37-41, Vol. 356	
	A65	TANDON et al., "HER-2/neu Oncogene Protein and Prognosis in Breast Cancer," <u>J. Clin. Oncol.</u> , 1989, pp. 1120-1128, Vol. 7	
	A66	TAVASSOLI et al., "c-erbB-2/c-erbA Co-amplification Indicative of Lymph Node Metastasis, and c-myc Amplification of High Tumor Grade, in Human Breast Carcinoma," <u>British J. of Cancer</u> , 1989, pp. 505-510, Vol. 60	
	A67	TOCKMAN et al., <u>Cancer Res.</u> , 1992, pp. 2711s-2718s, Vol. 52	
	A68	TRAHEY et al., "Molecular Cloning of Two Types of GAP Complementary DNA from Human Placenta," <u>Science</u> , 1988, pp. 1697-1700, Vol. 242	
	A69	TYERS et al., "Molecular Cloning and Expression of the Major Protein Kinase C Substrate of Platelets," <u>Nature</u> , 1988, pp. 470-473, Vol. 333	
	A70	VAN de VIJER et al., "Amplification of the new (c-erbB-2) Oncogene in Human Mammary Tumors Is Relatively Frequent and Is Often Accompanied by Amplification of the Linked c-erbA Oncogene," <u>Mol. Cel. Biol.</u> , 1987, pp. 2019-2023, Vol. 7	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10/679,694
Filing Date	10/07/2003
First Named Inventor	Benjamin L. Margolis
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0839

[illegible]Date
Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.